Punjab Samachar

Choroidal Neovascularization Market to Grow at a Substantial Growth Rate During the Forecast Period (2022-2032) – DelveInsight | Key Companies – Sylentis, Hoffmann-La Roche, Adverum Biotechnologies

 Breaking News
  • No posts were found

Choroidal Neovascularization Market to Grow at a Substantial Growth Rate During the Forecast Period (2022-2032) – DelveInsight | Key Companies – Sylentis, Hoffmann-La Roche, Adverum Biotechnologies

February 03
00:09 2023
Choroidal Neovascularization Market to Grow at a Substantial Growth Rate During the Forecast Period  (2022-2032) - DelveInsight | Key Companies - Sylentis, Hoffmann-La Roche, Adverum Biotechnologies
The Choroidal Neovascularization market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Choroidal Neovascularization pipeline products will significantly revolutionize the Choroidal Neovascularization market dynamics.

DelveInsight’s “Choroidal Neovascularization Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Choroidal Neovascularization, historical and forecasted epidemiology as well as the Choroidal Neovascularization market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Choroidal Neovascularization market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

 

To Know in detail about the Choroidal Neovascularization market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Choroidal Neovascularization Market Insights

 

Choroidal Neovascularization Overview

Choroidal neovascularization (CNV) involves the growth of new blood vessels that originate from the choroid through a break in the Bruch membrane into the sub–retinal pigment epithelium (subRPE) or sub retinal space. CNV is a major cause of visual loss. The symptoms of Choroidal neovascularization include a distortion or waviness of central vision or a gray/black/void spot in the central vision.

 

Some of the key facts of the Choroidal Neovascularization Market Report: 

  • The Choroidal Neovascularization market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • As per the study conducted by Wong TY et al., the Incidence of Choroidal neovascularization in individuals with pathologic myopia was reported to be 5.2%-11.3%, and was bilateral in approximately 15% of patients
  • As per the study conducted by Patrick Kaszubskiet al., in subjects aged 75 years and older, the Beaver Dam Eye Study reported a Geographic atrophy (GA) Incidence of 2% and a CNV Incidence of 5.2%
  • Key Choroidal Neovascularization Companies: Sylentis, Hoffmann-La Roche, Adverum Biotechnologies, and others
  • Key Choroidal Neovascularization Therapies: SYL180, Faricimab, ADVM-022, and others

 

Get a Free sample for the Choroidal Neovascularization Market Report –

https://www.delveinsight.com/sample-request/choroidal-neovascularization-market

 

Key benefits of the Choroidal Neovascularization Market report:

  1. Choroidal Neovascularization market report covers a descriptive overview and comprehensive insight of the Choroidal Neovascularization Epidemiology and Choroidal Neovascularization market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
  2. The Choroidal Neovascularization market report provides insights on the current and emerging therapies.
  3. Choroidal Neovascularization market report provides a global historical and forecasted market covering drug outreach in 7MM.
  4. The Choroidal Neovascularization market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Choroidal Neovascularization market.

 

Download the report to understand which factors are driving Choroidal Neovascularization epidemiology trends @ Choroidal Neovascularization Epidemiological Insights 

 

Choroidal Neovascularization Market  

The dynamics of the Choroidal Neovascularization market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032. 

“The dynamics of 7MM Choroidal Neovascularization therapeutics market is further expected to increase by the major drivers such as rising cases, technological advancements, and upcoming therapies in the forecast period [2022-2032]”

 

Choroidal Neovascularization Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Choroidal Neovascularization Epidemiology Segmentation:

The Choroidal Neovascularization market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Choroidal Neovascularization
  • Prevalent Cases of Choroidal Neovascularization by severity
  • Gender-specific Prevalence of Choroidal Neovascularization
  • Diagnosed Cases of Episodic and Chronic Choroidal Neovascularization

 

Choroidal Neovascularization Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Choroidal Neovascularization market or expected to get launched during the study period. The analysis covers Choroidal Neovascularization market uptake by drugs, patient uptake by therapies, and sales of each drug.  

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Choroidal Neovascularization Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Discover more about therapies set to grab major Choroidal Neovascularization market share @ Choroidal Neovascularization market forecast 

 

Choroidal Neovascularization Therapies and Key Companies

  • SYL1801: Sylentis
  • Faricimab: Hoffmann-La Roche
  • ADVM-022: Adverum Biotechnologies

 

Scope of the Choroidal Neovascularization Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Choroidal Neovascularization Companies: Sylentis, Hoffmann-La Roche, Adverum Biotechnologies, and others
  • Key Choroidal Neovascularization Therapies: SYL180, Faricimab, ADVM-022, and others
  • Choroidal Neovascularization Therapeutic Assessment: Choroidal Neovascularization current marketed and Choroidal Neovascularization emerging therapies
  • Choroidal Neovascularization Market Dynamics: Choroidal Neovascularization market drivers and Choroidal Neovascularization market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Choroidal Neovascularization Unmet Needs, KOL’s views, Analyst’s views, Choroidal Neovascularization Market Access and Reimbursement 

 

Table of Contents 

1. Choroidal Neovascularization Market Report Introduction

2. Executive Summary for Choroidal Neovascularization

3. SWOT analysis of Choroidal Neovascularization

4. Choroidal Neovascularization Patient Share (%) Overview at a Glance

5. Choroidal Neovascularization Market Overview at a Glance

6. Choroidal Neovascularization Disease Background and Overview

7. Choroidal Neovascularization Epidemiology and Patient Population

8. Country-Specific Patient Population of Choroidal Neovascularization 

9. Choroidal Neovascularization Current Treatment and Medical Practices

10. Choroidal Neovascularization Unmet Needs

11. Choroidal Neovascularization Emerging Therapies

12. Choroidal Neovascularization Market Outlook

13. Country-Wise Choroidal Neovascularization Market Analysis (2019–2032)

14. Choroidal Neovascularization Market Access and Reimbursement of Therapies

15. Choroidal Neovascularization Market Drivers

16. Choroidal Neovascularization Market Barriers

17.  Choroidal Neovascularization Appendix

18. Choroidal Neovascularization Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

To know more about Choroidal Neovascularization treatment, visit @ Choroidal Neovascularization Medications  

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting

Categories